PRESS RELEASE published on 02/06/2024 at 16:00, 1 year 1 month ago Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease Cantabio Pharmaceuticals, Inc. receives major grant from MJFF for the development of DJ-1 replacement therapy aimed at treating Parkinson's disease by increasing DJ-1 levels in patients and preventing disease progression Precision Medicine Cantabio Pharmaceuticals MJFF Grant DJ-1 Replacement Therapy Parkinson's Disease
Published on 04/04/2025 at 00:00, 1 hour 43 minutes ago Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025
Published on 04/03/2025 at 15:05, 10 hours 38 minutes ago Snowline Gold Closes Fully Subscribed C$20 Million Financing Of Flow-Through Shares
Published on 04/03/2025 at 15:00, 10 hours 43 minutes ago Kingstone Insurance Partners with Kyber Technologies Inc.
Published on 04/03/2025 at 15:00, 10 hours 43 minutes ago UniDoc Announces Debt Settlement and Renews Marketing Engagement
Published on 04/03/2025 at 15:00, 10 hours 43 minutes ago Xebra Brands’ Largest Shareholder Increases Stake as Company Explores Landmark Agricultural Agreement in Mexico
Published on 04/04/2025 at 00:04, 1 hour 38 minutes ago Carrefour relève son offre sur Carrefour Brésil
Published on 04/04/2025 at 00:04, 1 hour 38 minutes ago Carrefour raises its offer for Carrefour Brazil
Published on 04/03/2025 at 18:46, 6 hours 57 minutes ago Monthly disclosure of the total number of shares and voting rights - March 2025
Published on 04/03/2025 at 18:46, 6 hours 57 minutes ago Déclaration mensuelle des actions et droits de vote – Mars 2025
Published on 04/03/2025 at 18:00, 7 hours 43 minutes ago LDC : Chiffre d'affaires 2024-2025 : 6,3 milliards d’euros, au-delà des objectifs.
